Biosimilars Conference 2020

Biosimilars Conference 2020

January 30th–31st, 2020

At the moment, the uptake of biosimilars is still limited, especially in the US due to a lack of confidence towards biosimilars by some stakeholders; uncertainty about the interchangeability and substitution of biosimilars; and a hospital financing system that discourages the use of them. This year’s conference gathers biosimilars main players in the industry, representatives of pharmaceutical and biotechnological companies, professionals from governments, physicians and researchers to discuss updates in biosimilars’ development and regulatory restraints around them. Professionals and leaders will join an open conversation about barriers in developing biosimilars, cost of developing biosimilars; additionally, discover the way to introduce biosimilars to the market and provide sufficient knowledge for potential customers and consumers. Attendees will have the opportunity of networking with experts in the field while learning and sharing analytical views of the current biosimilars scene.

Key practical learning points of the summit

  • An overview of the current biosimilars market
  • Barriers in developing biosimilars
  • Cost of developing biosimilars.-
  • A summary of regulatory pathways in various geographic regions
  • How biosimilars is developing in different countries
  • An overview of approved biosimilars in the E.U., U.S., India, South Korea and Latin America.-
  • The market impact of biosimilars on their reference biologics
  • The top ten biologics on the focus of biosimilar developers
  • Ways to commercialize biosimilars
  • Implications of biosimilars in patient treatment

Who should attend

CEOs | CIOs | VPs | CTOs | Directors |Department Heads |Technical Analysts| Research Engineers | Specialists| Government officers specializing in:

  • Bioequivalence assessment
  • Biopharmaceuticals
  • Biologics/Biotechnology/ Biogenerics
  • Biosimilars Legal Affairs
  • Drug Pricing and Reimbursement
  • Regulatory Compliance
  • Preclinical and Clinical Development
  • Quality Affairs/ Quality Control
  • Biopharmaceuticals
  • Intellectual property
  • Clinical Immunology
  • New Product Development and Pharmacovigilance
  • Clinical Immunology
  • Immunology
  • Drug Safety
  • Preclinical Development
  • Vaccines Development
  • Validation
  • Analytical Characterization
  • Antibody Discovery
  • Oncology
  • Infection and Immunity
  • Risk Management
  • Clinical Program
  • Personalized Medicine
  • Portfolio Planning
  • Regulatory Affairs
  • Pharmacovigilance
  • Global Strategy and Antibody Engineering

Target audience

  • Pharmaceutical Companies,
  • Pharma Associations & Societies,
  • Biotechnology Experts/Business Entrepreneurs.
  • R&D, F&D Scientists
  • Intellectual Property Attorneys
  • Ph.D. and Post Doctorate Scholars

Proposed topics

Access new trends in the biosimilars industry

  • Which biosimilars have been approved?
  • An action plan for evaluation of similarity between proposed biosimilars and the original products
  • Recent legislation regarding biosimilars – Current status in Europe

Overcome challenges in the development and uptake of biosimilars

  • Solve uncertainty at the FDA over how to assess ‘similarity’ and ‘interchangeability’
  • Limit the number of interpartes reviews (IPRs) filed against patents for biologic reference products.
  • What is the future of the US biosimilars regarding barriers in legislation?

Commercialize biosimilars

  • Clinical development and trials of biosimilars
  • Product launches how to deal with competition and a breach of antitrust rules
  • Overview of the current biosimilar pricing
  • The role of the pharmacy benefit manager and the potential impact of co-pay accumulator adjustment program
  • Knowing your patients is the key factor for successful commercialization

Innovative manufacturing process and implementation of biosimilars

  • How biological treatments have transformed care for asthma patients
  • How patent policy impacts innovation and patients’ ability to benefit from an array of treatment options
  • Diabetes patients experience the impact of non-medical switching
  • Updated progress of treating cancer with biosimilars
  • The implications of nanosimilars and nanomedicines

For any enquiry on regards to special offers & group discounts please contact us directly at:

Event Schedule
Event Speakers
  • VP, TA Lead Rheumatology and Autoimmune Disorders Drug Development Services at ICON
  • General Manager at Biocon
  • Advanced Pharmacist at Kettering General Hospital NHS Foundation
  • Director at Endocrinology Associates
  • Assistant Manager II, pharmacovigilance and Clinical Development at Amgen
  • Partner, Head of Public Law Practice Baker McKenzie
  • Associate Director - Immunology, Medical Science Liaison/Medical Training Lead at Boehringer Ingelheim
  • Managing Director at Ashfield Healthcare
  • Dy Qualified Person for Pharmacovigilance for S-FDA (KSA), Global Medical Affairs at Julphar
  • Head of Quality at BioAtrum AG- A joint venture of Lonza and Sanofi
Event expired, so you can buy ticket at the moment.